Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025

Rhea-AI Summary

Bionano Genomics (NASDAQ: BNGO) recapped advances in optical genome mapping (OGM) showcased at the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston.

Thirteen studies presented OGM results across inherited disease, reproductive disorders, hematologic malignancies, and solid tumors, highlighting improved detection of structural variants (SVs), novel clinically relevant findings, and integration with cytogenetics and next-generation sequencing (NGS). Presentations also reported streamlined lab workflows and OGM application to fresh-frozen and FFPE samples using Bionano workflows and kits.

Key Figures

Studies at AMP 2025 13 studies Number of OGM-focused studies highlighted at AMP 2025

AMP 2025 dates November 11–15, 2025 Association for Molecular Pathology Annual Meeting dates

Market Reality Check

$1.54 Last Close

Volume Volume 185,973 vs. 20-day average 291,876 (relative volume 0.64) indicates subdued trading ahead of this news. low

Technical Shares at $1.68 are trading below the 200-day MA of $3.05 and far under the $22.8 52-week high.

Peers on Argus 1 Up

Sector peers showed mixed moves, with examples like LUCY up about 4.4% and others both positive and negative, suggesting stock-specific factors rather than a broad sector trend around this conference recap.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 03	Reimbursement update	Positive	+3.0%	CMS increased CPT code 81195 payment by 47% for OGM use.
Nov 13	Quarterly earnings	Positive	-8.1%	Q3 2025 revenue growth and cost reductions alongside maintained guidance.
Nov 06	Clinical publication	Positive	-4.7%	Study showed OGM can overcome key limits of targeted RNA-seq.
Oct 30	Earnings scheduling	Neutral	-1.6%	Announcement of date and webcast details for Q3 2025 call.
Oct 23	Conference data	Positive	-0.5%	ASHG 2025 presentations highlighted OGM’s role in genetic disease research.

Pattern Detected

Recent positive reimbursement, clinical, and scientific updates often saw flat to negative price reactions, while neutral scheduling news had limited impact, indicating a tendency toward skepticism on fundamentally positive headlines.

Recent Company History

Over the past few months, Bionano has reported several developments supporting adoption of optical genome mapping. On Dec 3, 2025, CMS boosted CPT code 81195 payment by 47%, and a Nov 6 publication showed OGM overcoming limits of targeted RNA‑seq in acute leukemia. Q3 2025 results on Nov 13 featured $7.4M revenue and cost controls, while October ASHG 2025 data highlighted OGM in diverse genetic diseases. Today’s AMP recap continues this pattern of scientific and clinical validation.

Market Pulse Summary

This announcement highlights Bionano’s role at AMP 2025, where 13 studies showcased optical genome mapping across inherited disease, reproductive health, and multiple cancer types. The news reinforces OGM’s ability to detect structural variants and integrate into cytogenetics and next‑generation sequencing workflows. In context of recent reimbursement gains and growing clinical evidence, key areas to watch include further adoption metrics, additional validating studies, and any updates on commercial traction.

Key Terms

optical genome mapping medical

"highlighted how optical genome mapping (OGM) can enhance the detection"

Optical genome mapping is a laboratory technique that produces a high-resolution picture of a person’s long DNA strands to find large structural changes such as missing, extra, or rearranged pieces. For investors, it matters because the method can improve diagnosis, speed development of genetic tests and therapies, and influence regulatory approvals and market demand for companies offering more accurate or faster genomic tools — think of it as a wide-angle camera that reveals large-scale defects traditional microscopes might miss.

structural variants medical

"enhance the detection of structural variants (SVs) with greater clarity"

Structural variants are large-scale changes in an organism’s DNA—such as missing, extra, flipped, or rearranged chunks of genetic material—that are like tearing out, duplicating, or reshuffling chapters in a book. Investors should care because these changes can drive or explain diseases, alter how well diagnostics and therapies work, and shift the commercial and regulatory outlook for drugs, tests, and gene-based treatments.

cytogenetic medical

"than traditional cytogenetic and molecular techniques"

Relating to the study of cells’ chromosomes — the bundled packages of DNA that act like a building’s blueprint for traits and behavior. Cytogenetic information shows whether those blueprints have missing, extra, or rearranged pieces, which can affect disease diagnosis, how patients respond to treatments, and whether a therapy is safe; for investors, that data can influence clinical trial outcomes, regulatory approval chances, and market potential.

next-generation sequencing medical

"into existing cytogenetics and next-generation sequencing (NGS) pipelines"

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

hematological malignancies medical

"reproductive disorders, hematological malignancies, and solid tumors"

Hematological malignancies are cancers that start in the blood-forming tissues or cells that circulate in the body, such as leukemia, lymphoma and multiple myeloma; think of them as harmful growths that disrupt the blood and immune systems rather than a single lump. Investors watch them because they define markets for drugs, diagnostics and treatments, influence clinical trial success and regulatory approval timelines, and can drive predictable long-term revenue or cost risks for healthcare companies.

solid tumors medical

"hematological malignancies, and solid tumors"

Solid tumors are abnormal masses of tissue that form when cells in organs or glands grow uncontrollably, like a dense knot in a garden plant rather than something spread through the water. For investors, they matter because treatments, diagnostics and surgeries targeting solid tumors drive large clinical programs, regulatory reviews and potential revenue streams; success or failure in treating these tumors can significantly affect a company’s drug pipeline, valuation and market opportunity.

ffpe medical

"from FFPE Samples Using Bionano G2 FFPE DNA Kit and the Ionic System"

FFPE stands for formalin-fixed, paraffin-embedded, a standard laboratory method for preserving tissue samples by chemically fixing them and enclosing them in wax so they keep their structure over time. Think of it like embedding a pressed flower in wax to preserve its shape and details. For investors, FFPE matters because many diagnostic tests, drug development studies and biomarker analyses rely on these preserved samples; their quality and compatibility with laboratory assays affect clinical validation, regulatory approval and the commercial value of pathology and diagnostics products.

chromoanagenesis medical

"Optical Genome Mapping Reveals Chromoanagenesis in Congenital Disorders"

Chromoanagenesis is a sudden, catastrophic reshuffling of one or a few chromosomes where DNA is broken and stitched back together in the wrong order, creating many complex mutations in a single event. It matters to investors because this kind of genome damage can drive aggressive disease, alter how patients respond to treatments, and affect the value of diagnostics or therapies tied to specific genetic targets — like a book whose pages are torn out and randomly reinserted, changing the story.

AI-generated analysis. Not financial advice.

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key presentations at the conference highlighted how optical genome mapping (OGM) can enhance the detection of structural variants (SVs) with greater clarity and sensitivity than traditional cytogenetic and molecular techniques. Through platform presentations and poster sessions, multiple researchers emphasized the expanding utility of OGM in inherited disease testing, reproductive disorders, hematological malignancies, and solid tumors.

Key Highlights from AMP 2025:

A total of thirteen studies, noted below, highlighted the increasing use of OGM and its capacity to detect novel and clinically relevant structural variants, either independently or complementary to other molecular and cytogenetic methods. When taken together, these results demonstrate OGM’s potential strength as a high-resolution, genome-wide technique for uncovering genetic mechanisms that drive complex diseases.

Researchers also presented data showing streamlined laboratory workflows and successful integration of OGM into existing cytogenetics and next-generation sequencing (NGS) pipelines, reinforcing its utility in both clinical and translational research settings.

1. Utility of Optical Genome Mapping in a Case of Recurrent Pregnancy Loss​ – Amira Othman, Queens University, Canada
   
2. Comprehensive Molecular Profiling of Pediatric Low-Grade Gliomas: A Multi-Omics Approach to Uncover Novel Targets – Madhumala Sadanandappa, Geisel School of Medicine at Dartmouth, US
   
3. Development of a Combined Protocol for Simultaneous Purification of DNA or RNA from FFPE Samples Using Bionano G2 FFPE DNA Kit and the Ionic System – Annick Lalonde, CHU de Quebec, Canada
   
4. Evaluating Recurrent Pregnancy Loss using Optical Genome Mapping integrated with gene-specific Structural Variant profiling​ – Debopriya Chakraborty, Dartmouth Hitchcock Medical Center​, US
   
5. Establishing a Comprehensive Approach for WES-Negative Paediatric Population with Suspected Neurodevelopmental Disorder – Yeseul Kim, Seoul National University College of Medicine, Korea
   
6. Improved Algorithms for Optical Genome Mapping Workflows in Constitutional Disease and Oncology Applications – Andy Wing Chung Pang​, Bionano Genomics, US
   
7. OGM Complementarity with Next-generation Sequencing (NGS) to Improve Genomic Assessment in Multiple Myeloma ​– Sara Akhavanfard, Case Western Reserve University​, US
   
8. Optical Genome Mapping Enables Genome-wide Structural Variant Detection Using Fresh-Frozen Tissue​ – Shrivaprasad H. Sathyanarayana, Dartmouth Hitchcock Medical Center-Dartmouth Health, US
   
9. Optical Genome Mapping Uncovers Variants in an Adult T-cell Acute Lymphoblastic Leukemia (T-ALL) – Amanda Maxfield, Geisel School of Medicine at Dartmouth, US
   
10. Optical Genome Mapping Reveals Chromoanagenesis in Congenital Disorders –Gordana Raca, Children's Hospital Los Angeles, US
    
11. Optical Genome Mapping Unravels Cryptic Rearrangements in Acute Leukemias – Lina Shao, University of Michigan, US
    
12. Synopsis of Optical Genome Mapping Quality Benchmarks in 200 Cancer Samples – Kyle Tonseth, Dartmouth Health​, US
    
13. Validation of Optical Genome Mapping for Lymphoid Malignancies​ – Maged Zeineldin, Johns Hopkins University School of Medicine​, US

The scientific program for the event is available at the AMP website linked here: https://amp25.amp.org/program/program-highlights/

“We believe the work presented at AMP demonstrates how OGM is reshaping the landscape of cytogenomics and molecular pathology. As we continue to innovate and expand our platform, we’re committed to enabling a future where comprehensive structural variant analysis is routine, efficient, and accessible to every lab,” commented Erik Holmlin, PhD, president and CEO of Bionano.

For more information on Bionano’s OGM solutions, visit www.bionano.com.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit www.bionano.com or www.bionanolaboratories.com.

Bionano’s products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “can,” “capacity,” “believe,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things; the ability and utility of OGM to detect SVs with greater clarity and sensitivity than traditional cytogenetic and molecular techniques; the potential for increased use of OGM; the ability and utility of OGM to detect novel and clinically relevant structural variants, either independently or complementary to other molecular and cytogenetic methods; the ability and utility of OGM as a high-resolution, genome-wide technique for uncovering genetic mechanisms that drive complex diseases; the ability and utility of OGM to reshape the landscape of cytogenomics and molecular pathology; our expectations regarding product uptake, revenue, flowcell usage by customers we consider to be routine users of OGM, market development and OGM adoption, including as evidenced through publications highlighting the utility and applications of OGM, our commercial prospects and future financial and operating results; continued research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies; our ability to drive adoption of OGM and our technology solutions; and any other statements that are not of historical fact. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the ability and utility of OGM to detect SVs with greater clarity and sensitivity than traditional cytogenetic and molecular techniques; the potential for increased use of OGM; the failure of OGM to detect novel and clinically relevant structural variants, either independently or complementary to other molecular and cytogenetic methods; the failure of OGM to be a high-resolution, genome-wide technique for uncovering genetic mechanisms that drive complex diseases; the failure of OGM to reshape the landscape of cytogenomics and molecular pathology; future publications or presentations that contradict the findings of the publications or presentations referenced in this press release; our failure to drive adoption of OGM and our technology solutions; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; study results that differ or contradict the results mentioned in this press release; the risk that we are not able to complete a strategic transaction that would increase stakeholder value; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties including those described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law. 

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
Kelly Gura
Gilmartin Group
+1 (212) 229-6163
IR@bionano.com

FAQ

What did Bionano Genomics (BNGO) present at AMP 2025?

Bionano highlighted OGM studies showing enhanced detection of structural variants across inherited disease, reproductive disorders, hematologic malignancies, and solid tumors.

When and where did AMP 2025 presentations featuring BNGO occur?

The presentations took place at the AMP Annual Meeting in Boston, November 11-15, 2025.

How many AMP 2025 studies featured optical genome mapping with BNGO methods?

A total of thirteen studies at AMP 2025 showcased OGM applications and results.

Did AMP 2025 data show OGM integrating with next-generation sequencing for BNGO?

Yes; several presentations reported OGM complementing NGS to improve genomic assessment and workflows.

Which clinical sample types did BNGO-related AMP 2025 posters report OGM working with?

Presentations reported OGM on fresh-frozen tissue and workflows for FFPE samples using Bionano kits.

Where can investors find more information about Bionano's OGM solutions after AMP 2025?

For further information, visit Bionano's website at www.bionano.com.